## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.5% below STRENGTH zone (3.0-6.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. New Henry Schein CEO expected by mid-January as Bergman extends tenure**
- Source: MedTech Dive | 20260105T151904 | Neutral | Relevance: 100%
- Henry Schein CEO Stanley Bergman has extended his tenure past his original December 2025 retirement date as the company finalizes its search for a successor. The company anticipates appointing a new CEO by mid-January, with Bergman stepping down once a replacement is found. Bergman, who has led Henry Schein for over 35 years, significantly grew the company's revenue and market valuation since taking it public in 1995.

**2. The Truth About Henry Schein Inc: Quiet Dental Giant Or Sleeper Stock You’re Sleeping On?**
- Source: AD HOC NEWS | 20260105T170914 | Bullish | Relevance: 100%
- Henry Schein Inc. is presented as a "quiet dental giant" and a "sleeper stock" in the healthcare supply sector. The article explores whether this low-key company, which provides supplies, equipment, and software to dental and medical practices, is a worthwhile investment despite not having the viral appeal of tech stocks. It highlights the company's steady performance, recurring revenue model, and potential as a defensive play for long-term investors.

**3. The Truth About Henry Schein Inc: Quiet Dental Giant Or Sleeper Stock You’re Sleeping On?**
- Source: AD HOC NEWS | 20260105T170817 | Bullish | Relevance: 100%
- Henry Schein Inc (HSIC) is presented as a quiet dental giant that, despite lacking viral social media hype, offers a stable investment opportunity in the healthcare supply sector. The article details its business model, which includes distributing medical supplies, selling equipment and tech, and offering software services, highlighting the "sticky" nature of its client relationships. It concludes that Henry Schein is a "must-watch" for investors seeking defensive plays and long-term stability in their portfolio, rather than a high-growth, high-volatility stock.

**4. Titanium & Titanium Alloys Dental Implants Market is expected**
- Source: openPR.com | 20260105T070956 | Somewhat-Bullish | Relevance: 60%
- The global Titanium & Titanium Alloys Dental Implants Market, valued at US$ 5.86 billion in 2023, is projected to reach US$ 12.33 billion by 2031, with a CAGR of 9.8% from 2024-2031. This growth is driven by the biocompatibility, strength, and corrosion resistance of titanium implants, alongside increasing dental disorders, an aging population, and rising awareness of advanced implant solutions. Key market players include Institut Straumann AG, Dentsply Sirona, and Zimmer Biomet, with recent developments focusing on advanced alloys, 3D-printing, and strategic acquisitions to enhance market offerings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +3.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 0.88 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 14.9 |
| Current P/E | 16.0 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.3% to 2.5% (+3.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.5pp (needs >3.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +F0N (Breakout).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.46% (CS: 73) | Neutral |
| RSI_14 | 66.7 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.082x | Above |
| vs SMA200 | 1.129x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $78.54
- **Stop Loss:** $75.80 (3.5% risk)
- **Target:** $81.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 314
- **Position Value:** $24,661.56
- **Portfolio %:** 24.66%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*